Cabot Small-Cap Confidential Special Bulletin

You are trying to access subscriber-only content.

If you are a subscriber, log in here.

If you are not a subscriber, click here for your subscription. Subscribers will have unlimited access to our magazine articles and more!

Article Excerpt

Cardlytics (CDLX) reported Q4 2020 numbers this morning that surpassed revenue expectations by roughly 10% and missed modestly on earnings. Revenue was down 3.2% to $67.1 million (beating by $6.2 million) while adjusted EPS of -$0.05 missed by $0.02. Management gave 2021 guidance that called for revenue of $250 million to $275 million, which straddles consensus expectations of $260 million (up 40%).


You must be logged in to post a comment.